In re Intuniv Antitrust Litig., No. 16-cv-12653 (D. Mass.)

In the Intuniv case, Faruqi & Faruqi represents a class of direct purchasers of Shire’s Intuniv (guanfacine), a prescription drug used to treat attention deficit hyperactivity disorder.  The class also includes direct purchasers of generic versions of Intuniv from Actavis, Shire’s former co-defendant and alleged co-conspirator.  Actavis has already settled for $19.9 million while litigation as to Shire remains ongoing.  The complaint alleges that Shire entered a reverse payment patent settlement with Actavis to delay launching its first-filed generic to compete with Shire’s $300+ million a year Intuniv tablets.  Such an agreement violates §§ 1 and 2 of the Sherman Act.